Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor

Kalle E. Mattila, Siru Mäkelä, Soili Kytölä, Emma Andersson, Pia Vihinen, Susan Ramadan, Tanja Skyttä, Leena Tiainen, Meri Sisko Vuoristo, Kristiina Tyynelä-Korhonen, Jussi Koivunen, Laura Kohtamäki, Kristiina Aittomäki, Micaela Hernberg

    Research output: Contribution to journalArticleScientificpeer-review

    3 Citations (Scopus)

    Abstract

    Background: Detectable circulating tumor DNA (ctDNA) has been associated with worse prognosis in melanoma patients. Material and methods: We studied plasma ctDNA as a prognostic biomarker in 19 patients with metastatic melanoma and a detectable tumor mutation (13 BRAF, 5 NRAS, and 1 KRAS). Patients had received chemotherapy, interferon-alpha, and vemurafenib in a prospective clinical trial. Mutant allele frequency (MAF %) was determined with droplet digital PCR from pretreatment and sequential plasma samples. Results: Higher pretreatment plasma ctDNA levels (MAF ≥3%) and detectable plasma ctDNA levels (MAF >0%) at the time of radiologically confirmed best objective response were associated with poor prognosis even when accounting for other relevant prognostic factors including performance status, tumor mutation, metastasis stage, and lactate dehydrogenase levels in multivariable analysis. Conclusion: Higher pretreatment plasma ctDNA levels and sustained detectable plasma ctDNA levels during treatment indicated poor prognosis in metastatic melanoma patients.

    Original languageEnglish
    Pages (from-to)1263-1267
    Number of pages5
    JournalActa Oncologica
    Volume61
    Issue number10
    DOIs
    Publication statusPublished - 2022
    Publication typeA1 Journal article-refereed

    Keywords

    • Biomarker
    • ctDNA
    • droplet digital PCR
    • melanoma
    • survival

    Publication forum classification

    • Publication forum level 1

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Radiology Nuclear Medicine and imaging

    Fingerprint

    Dive into the research topics of 'Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor'. Together they form a unique fingerprint.

    Cite this